Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1441 - Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review

Date

10 Sep 2017

Session

Poster display session

Presenters

Ahmad Tarhini

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

A. Tarhini1, C. Macahilig2, C. Atzinger3, K. Gupte-Singh4, C. Solem3, S. Rao4

Author affiliations

  • 1 Division Of Hematology-oncology, University of Pittsburgh Medical Center, 15232 - Pittsburgh/US
  • 2 Research Operations, Medical Data Analytics, 00 - Parsippany/US
  • 3 Global Health Economics And Outcomes Research, Pharmerit International, 20814 - Bethesda/US
  • 4 Health Economics Outcomes Research, Bristol-Myers Squibb, Princeton/US
More

Resources

Abstract 1441

Background

The advanced melanoma treatment landscape has significantly changed with approval of ipilimumab (IPI) and nivolumab (NIVO). This analysis aimed to describe real-world characteristics and treatment patterns of patients (pts) prescribed IPI, NIVO, or NIVO+IPI.

Methods

This interim analysis of an observational, retrospective, multisite study collected data for US pts diagnosed with unresectable or metastatic melanoma who received IPI, NIVO, or NIVO+IPI (index) between January 2015 and May 2016. Demographics and treatment patterns were abstracted from medical records through most recent visit (≥6 months). Data were descriptively reported.

Results

Of 115 pts from 20 sites in the USA, 43 received IPI (mean±SD age 61.5±11.3 years, 51.2% female, 86.0% ECOG PS ≤ 1), 41 NIVO (age 65.9±13.7 years, 48.8% female, 90.3% ECOG PS ≤ 1), and 31 NIVO+IPI (age 57.1±11.3 years, 48.4% female, 100% ECOG PS ≤ 1). Tests for BRAF and PD-L1 were conducted in 98.3% and 39.1% of pts, respectively; 14.3%, 6.7%, and 12.2% of tested IPI, NIVO, and NIVO+IPI patients had a BRAF mutation, and 60%, 50%, and 79.0% of IPI, NIVO, and NIVO+IPI patients had a positive PD-L1 status. The index treatment was first line for 98.3% of pts; mean±SD days from advanced diagnosis to treatment initiation was 21.5±16.1 days for IPI, 55.1±68.6 for NIVO, and 41.5±68.6 for NIVO+IPI. The most common rationales for treatment initiation across treatments were improved efficacy (73.9%) and documented survival benefit (44.4%). Dose delays occurred in 9.3% of IPI pts (mean delay 12.7 days) and 6.5% of NIVO pts (mean delay 45 days); no NIVO+IPI pts had dose delays. At 6 months, 16% of pts remained on IPI, 85% remained on NIVO, and 71% remained on the NIVO portion of the NIVO+IPI regimen. Permanent discontinuation of treatment prior to completing planned courses of therapy was relatively infrequent (IPI: 16%, NIVO: 26%, NIVO+IPI: 19%), possibly reflecting improved experience in toxicity assessment and management.

Conclusions

Within this real-world cohort, a minority of pts discontinued NIVO or NIVO+IPI by 6 months. This research sheds light on current treatment patterns for IPI, NIVO, and their combination.

Clinical trial identification

CA209-983

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

A. Tarhini: Served as a consultant or advisor for Bristol-Myers Squibb; received institutional research funding from Amgen, Bristol-Myers Squibb, Incyte, MSD, Novartis, and Prometheus Laboratories. C. Macahilig: Employed by Medical Data Analytics, where she provides study design and data collection. C. Atzinger: Received personal fees from Bristol-Myers Squibb; employee of Pharmerit International. K. Gupte-Singh: Employee of Bristol-Myers Squibb and has stock/ownership in Bristol-Myers Squib. C. Solem: Institution received consulting fees from Bristol-Myers Squibb to conduct this research. S. Rao: Employed of Bristol-Myers Squibb and has stock/ownership in Bristol-Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.